Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2008

View Archived Issues

Human somatic cells can be induced into pluripotent stem cells without nuclear transfer

Neuroprotective effects of phosphorylated PRAS40 after spinal cord injury

New PPAR agonists described in recent patent

Novel diagnostic agents disclosed in recent patent from University of California, Oakland

Aastrom initiates patient treatment with stem cell therapy for dilated cardiomyopathy

Targeting the endothelin B receptor may improve the efficacy of tumor immune therapy

Intercell and PATH enter new collaboration for development of malaria vaccine

ActivBiotics extends deadline for sale of company assets until March 2008

Kamada announces completion of phase I studies with aerosolized alpha-1 antitrypsin

DelSite's nasal powder vaccine GelVac to move into phase I clinical trial later this year

Juvaris and Centers for Disease Control and Prevention enter agreement for H5N1 vaccine

Can-Fite expands studies to further investigate efficacy of CF-101 in treating uveitis

MAP completes SPA with FDA for phase III clinical trial of MAP-0004 for migraine

Cerimon initiates phase II/III trials of once-daily diclofenac sodium patch for pain

Novel treatment for spinal cord disorders reported in recent Sia Peptides patent

Denmark approves phase I clinical trials of PlGF antibody TB-403 in cancer

FDA approves ZymoGenetics' Recothrom commercialization

Schering-Plough files NDA for sugammadex in Japan

SGX announces that enrollment has begun in phase I clinical trials of SGX-523 for cancer

EPIX reports revised results from its phase IIa clinical trial of PRX-03140 in AD

XenoPort and GSK report top-line results for XP-13512 in the treatment of RLS

Shire launches Fosrenol in Spain, completing launch roll-out in E.U. markets

Dosing of Tracon's TRC-105 begins in cancer patients enrolled in a phase I trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...